Previous close | 5,146.00 |
Open | 5,160.00 |
Bid | 5,146.00 x 200 |
Ask | 5,147.00 x 34100 |
Day's range | 5,152.00 - 5,227.00 |
52-week range | 2,637.00 - 5,379.00 |
Volume | |
Avg. volume | 1,375,194 |
Market cap | 59.502B |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.86 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 28 Nov 2017 |
1y target est | 14.86 |
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time).